Sagar B Dugani1, Luke R Christenson2, Jeremiah A Aakre2, Hai H Bui3, Adrian Vella4, Michelle M Mielke5. 1. Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, United States; Division of Health Care Delivery Research, Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, United States. 2. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States. 3. Eli Lilly and Company, Indianapolis, IN, United States. 4. Division of Endocrinology, Mayo Clinic, Rochester, MN, United States. 5. Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States; Department of Neurology, Mayo Clinic, Rochester, MN, United States. Electronic address: mielke.michelle@mayo.edu.
Abstract
AIMS: The role of ceramides in the pathogenesis of type 2 diabetes mellitus (T2DM) is incompletely characterized. Given that ceramides represent therapeutic targets to disrupt the euglycemia-T2DM transition, we aimed to characterize their association with prevalent and incident T2DM in a novel cohort. METHODS: We examined the cross-sectional and longitudinal association of baseline ceramides with prevalent and incident T2DM among 1423 adults (47% women; median (range) baseline age 72 (51-95) years) in the Mayo Clinic Study of Aging cohort. We examined the associations of ceramides with prevalent T2DM (adjusted odds ratio [95% confidence interval]) at baseline and incident T2DM (adjusted hazard ratio [95% confidence interval]) during median follow-up of 6.2 years, after adjusting for demographic and metabolic factors. RESULTS: Among 1423 adults, there were 222 prevalent and 37 incident cases of T2DM. In cross-sectional analyses, higher levels of ceramide C16:0 were associated with lower odds of prevalent T2DM (aOR 0.84 [0.71-0.99];P = 0.03) whereas C18:0 (aOR 1.27 [1.06-1.42];P = 0.01), C18:0/16:0 (aOR 1.41 [1.22-1.62]; P < 0.001) and C18:0/24:0 (aOR 1.22 [1.05-1.41]; P = 0.01) were associated with higher odds. In Cox hazard regression models, C18:0/16:0 (aHR 1.63 [1.26-2.10];P < 0.001) and C18:0 (aHR 1.53 [1.12-2.08];P = 0.01) were associated with increased risk of incident T2DM. CONCLUSIONS: In this prospective population-based cohort, ceramides were associated with prevalent T2DM (C16:0,C18:0, C18:0/C16:0 ratio, C18:0/C24:0 ratio) and incident T2DM (C18:0, C18:0/C16:0 ratio) and could suggest targets for the primary and secondary prevention of T2DM.
AIMS: The role of ceramides in the pathogenesis of type 2 diabetes mellitus (T2DM) is incompletely characterized. Given that ceramides represent therapeutic targets to disrupt the euglycemia-T2DM transition, we aimed to characterize their association with prevalent and incident T2DM in a novel cohort. METHODS: We examined the cross-sectional and longitudinal association of baseline ceramides with prevalent and incident T2DM among 1423 adults (47% women; median (range) baseline age 72 (51-95) years) in the Mayo Clinic Study of Aging cohort. We examined the associations of ceramides with prevalent T2DM (adjusted odds ratio [95% confidence interval]) at baseline and incident T2DM (adjusted hazard ratio [95% confidence interval]) during median follow-up of 6.2 years, after adjusting for demographic and metabolic factors. RESULTS: Among 1423 adults, there were 222 prevalent and 37 incident cases of T2DM. In cross-sectional analyses, higher levels of ceramide C16:0 were associated with lower odds of prevalent T2DM (aOR 0.84 [0.71-0.99];P = 0.03) whereas C18:0 (aOR 1.27 [1.06-1.42];P = 0.01), C18:0/16:0 (aOR 1.41 [1.22-1.62]; P < 0.001) and C18:0/24:0 (aOR 1.22 [1.05-1.41]; P = 0.01) were associated with higher odds. In Cox hazard regression models, C18:0/16:0 (aHR 1.63 [1.26-2.10];P < 0.001) and C18:0 (aHR 1.53 [1.12-2.08];P = 0.01) were associated with increased risk of incident T2DM. CONCLUSIONS: In this prospective population-based cohort, ceramides were associated with prevalent T2DM (C16:0,C18:0, C18:0/C16:0 ratio, C18:0/C24:0 ratio) and incident T2DM (C18:0, C18:0/C16:0 ratio) and could suggest targets for the primary and secondary prevention of T2DM.
Authors: Johannes Kornhuber; Christian P Müller; Katrin Anne Becker; Martin Reichel; Erich Gulbins Journal: Trends Pharmacol Sci Date: 2014-05-01 Impact factor: 14.819
Authors: Maura E Walker; Vanessa Xanthakis; Lynn L Moore; Ramachandran S Vasan; Paul F Jacques Journal: Am J Clin Nutr Date: 2020-02-01 Impact factor: 7.045
Authors: Rosebud O Roberts; David S Knopman; Scott A Przybelski; Michelle M Mielke; Kejal Kantarci; Gregory M Preboske; Matthew L Senjem; Vernon S Pankratz; Yonas E Geda; Bradley F Boeve; Robert J Ivnik; Walter A Rocca; Ronald C Petersen; Clifford R Jack Journal: Neurology Date: 2014-03-19 Impact factor: 9.910
Authors: Mika Hilvo; Lars Wallentin; Tatevik Ghukasyan Lakic; Claes Held; Dimple Kauhanen; Antti Jylhä; Johan Lindbäck; Agneta Siegbahn; Christopher B Granger; Wolfgang Koenig; Ralph A H Stewart; Harvey White; Reijo Laaksonen Journal: J Am Heart Assoc Date: 2020-05-07 Impact factor: 5.501